Mitochondrial disease is a group of genetic disorders in which the mitochondria, the structures inside your cells that convert food into usable energy, fail to work properly. At least 1 in 5,000 people are affected, though the true number is likely higher because many cases go undiagnosed. Because nearly every cell in your body relies on mitochondria for energy, these diseases can damage the brain, muscles, heart, liver, kidneys, eyes, and ears, often simultaneously.
How Mitochondria Power Your Cells
Mitochondria break down sugars and fats to produce ATP, the molecule your cells use as fuel for virtually everything they do. When glucose is processed through the full mitochondrial system using oxygen, a single molecule of glucose yields roughly 30 molecules of ATP. That is about 15 times more energy than cells can extract without mitochondria. Your cells constantly shuttle ATP out of mitochondria into the rest of the cell and send spent fuel back in for recharging.
This process is not optional. If mitochondrial activity drops significantly, ATP levels fall, energy-dependent reactions stop, and cells begin to die. The organs that consume the most energy, like the brain, heart, and skeletal muscles, are hit first and hardest. That explains why mitochondrial disease so often targets those systems.
Two Genetic Sources of Disease
Mitochondria have their own small genome, separate from the DNA in the cell’s nucleus. Mitochondrial DNA (mtDNA) is inherited exclusively from your mother. But here’s what makes diagnosis complicated: more than 90% of the proteins mitochondria need to function are actually encoded by nuclear DNA, which you inherit from both parents. So mitochondrial disease can result from mutations in either genome.
When the mutation is in mtDNA, inheritance follows the maternal line. A single cell contains many copies of mtDNA, and mutated and normal copies can coexist side by side, a situation called heteroplasmy. The ratio of mutated to healthy copies helps determine how severe symptoms become. Even low-level mutations inherited from a mother can act as a starting point, with additional damage accumulating over a lifetime.
When the mutation is in nuclear DNA, the disease follows standard inheritance patterns and can be passed on by either parent. The energy-producing machinery inside mitochondria is built from components encoded by both genomes working together. Complex I alone, one of five major components in the energy chain, requires products from at least 7 mitochondrial genes and 25 nuclear genes. A defect in any one of them can disrupt the entire system.
Symptoms Across Multiple Organs
Because energy-hungry tissues suffer most, muscle weakness, exercise intolerance, and muscle pain are among the most common complaints. Neurological symptoms are also frequent: seizures, migraines, developmental delays in children, and progressive cognitive decline. Heart problems, particularly cardiomyopathy (a weakening of the heart muscle), can develop as a serious complication.
Other symptoms include vision and hearing loss, breathing difficulties, fainting, vomiting, and poor growth in children. The pattern varies enormously from person to person. Two people with the same genetic mutation can have very different experiences depending on how many of their mitochondria carry the defect and which tissues are most affected.
Major Types of Mitochondrial Disease
Several well-recognized syndromes fall under the mitochondrial disease umbrella, each with a somewhat distinct pattern.
- Leigh syndrome typically appears between 3 months and 2 years of age and progresses rapidly. Early signs include loss of appetite, vomiting, irritability, and loss of motor skills, followed by generalized weakness and episodes of lactic acid buildup that can impair breathing and kidney function.
- MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) usually begins in childhood or early adulthood. It causes recurrent episodes that mimic strokes, producing temporary vision loss or difficulty speaking, along with seizures and progressive brain injury. The mean age of death in one adult cohort was about 42 years, though the range spanned from the early 20s to late 70s.
- MERRF (myoclonus epilepsy with ragged red fibers) starts in late childhood or adolescence. It causes involuntary muscle jerks, seizures, coordination problems, hearing loss, and short stature.
- Kearns-Sayre syndrome is caused by large deletions in mtDNA and often leads to heart conduction problems. In studied cases, patients died of cardiopulmonary complications between ages 40 and 66.
- CPEO (chronic progressive external ophthalmoplegia) primarily affects eye movement and eyelid muscles. It tends to be milder, with a median age of death around 59 in one cohort, and some forms are not associated with reduced life expectancy at all.
How It Is Diagnosed
Diagnosing mitochondrial disease is notoriously difficult because symptoms overlap with many other conditions. The process typically starts with blood and urine tests looking for elevated lactate, abnormal amino acid profiles, and other metabolic markers that suggest the energy-production chain is not working correctly.
Genetic testing has become the preferred next step. Next-generation sequencing of the full mitochondrial genome is now considered the gold standard because it can detect point mutations, deletions, and even low levels of heteroplasmy in a single test. If that comes back negative, sequencing of nuclear genes known to affect mitochondrial function is recommended, and whole-exome sequencing (scanning all protein-coding genes) may follow if panels targeting known genes don’t reveal an answer.
Muscle biopsy was long considered the definitive diagnostic tool, and it still plays a role when genetic testing is inconclusive. A small sample of muscle tissue is examined under a microscope and tested biochemically for signs of mitochondrial dysfunction. Brain MRI and heart imaging are used to assess organ-specific damage once a diagnosis is suspected.
Treatment and Management
There is no cure for most forms of mitochondrial disease, and treatment has historically focused on managing symptoms and supporting energy production with nutritional supplements. The most commonly used supplements are CoQ10 (ubiquinol is the preferred form due to better absorption), riboflavin (vitamin B2), and sometimes L-carnitine, though L-carnitine has fallen out of routine use because of concerns about cardiovascular risks with long-term supplementation.
CoQ10 doses for adults typically range from 50 to 600 mg daily, while riboflavin is generally given at 50 to 400 mg daily. These are not standardized prescriptions. Doctors adjust doses based on lab monitoring and individual response. This supplement regimen, sometimes called a “mitochondrial cocktail,” aims to support whatever residual energy-producing capacity the mitochondria retain.
A significant milestone came when the FDA approved the first drug specifically for a mitochondrial disease subtype: thymidine kinase 2 deficiency (TK2d), a very rare form that causes progressive muscle weakness. In clinical data, only 4% of treated patients died over the study period compared with 36% of untreated patients, and mean 10-year survival improved from 5.7 years to 9.6 years. This approval, while narrow, represents the first targeted therapy to reach patients with a mitochondrial disease.
Prognosis and What Affects It
Outcomes vary dramatically depending on the specific mutation, which organs are involved, and when symptoms first appear. Disease that begins in early childhood tends to be multisystem and progresses quickly. Adult-onset forms are more likely to follow one of the recognized syndromes and can have a more variable course, ranging from mild disability to life-threatening complications.
Cardiac involvement is one of the strongest predictors of reduced life expectancy. In MELAS and Kearns-Sayre syndrome, heart complications are a leading cause of death. Respiratory failure, sometimes triggered by seizures or infections, is another major risk. By contrast, people with milder forms like isolated CPEO caused by point mutations can live into their 60s and 70s without a dramatically shortened lifespan.
The ratio of mutated to healthy mitochondrial DNA within your cells also matters. Because this ratio can differ between tissues and can shift over time, the same genetic mutation may produce vastly different outcomes in different people, even within the same family.